Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

Neoadjuvant Teripalimab Plus Chemotherapy in Local Advanced Esophageal Squamous Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03985670
• Other study ID #: HenanCH immunotherapy001
• Status: Recruiting
• Phase: Phase 2
• Start date: July 10, 2019
• Est. completion date: April 30, 2023

Study information

• Verified date: June 2019
• Source: Henan Cancer Hospital
• Contact: Quanli Gao, Dr.
• Phone: +86-15038171966
• Email: gaoquanli2015[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The prognosis of locally advanced esophageal squamous cell carcinoma is poor,the role of chemotherapy as neoadjuvant therapy in locally advanced esophageal cancer has been established, which can convert some unresectable esophageal cancer into resectable esophageal cancer.PD-1 antibody has been shown to improve the pathological complete response rate in NSCLC, however, the data in neoadjuvant of esophageal squamous carcinoma is relatively rare. This study was designed to know the value of PD-1 antibody in neoadjuvant therapy of esophageal cancer.

Description:

The prognosis of locally advanced esophageal squamous cell carcinoma is poor, the 5-year survival rate is less than 50%. It is necessary to conduct studies in these patients to reduce the rate of postoperative recurrence and prolong the disease-free survival. The role of chemotherapy as neoadjuvant therapy in locally advanced esophageal cancer has been established, which can convert some unresectable esophageal cancer into resectable esophageal cancer. The PD-1 antibody, teripalimab, is an immunological checkpoint inhibitor that has shown clinical efficacy in advanced esophageal cancer, but there has been relatively few data on neoadjuvant therapy. This study was designed to comprehend the pathological complete response rate, disease-free survival, and safety of neoadjuvant therapy with chemotherapy plus teriprilin patients with locally advanced esophageal squamous cell carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: April 30, 2023
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Thoracic esophageal squamous cell carcinoma diagnosed by pathology

• no distant metastasis, the diseases could be resected or potentially resectable assessed by thoracic oncologist

• ECOG score 0-1

• clinical stage is stage II, III, and IVa according to AJCC 8.0

• expected lifespan > 3 months

• enough organ function

• normal blood pressure, for patients with hypertension, the blood pressure should be controlled in normal level by antihypertension

• the fasting blood sugar should be = 8mmol / L for diabetic patients

• no other serious diseases (such as autoimmune diseases, immunodeficiencies, organ transplants) that conflict with this study

• no history of other malignant tumors

• women of childbearing period must be tested negative for blood pregnancy within 7 days, and subjects of childbearing age must use appropriate contraceptive measures during the trial period and within 6 months after the trial;

• The patient agrees to participate in the clinical study and sign the Informed Consent Form.

Exclusion Criteria:

• suffering from serious infectious diseases within 4 weeks before enrollment;

• patients with bronchial asthma requires intermittent use of bronchodilators or medical interventions;

• usage of immunosuppressants before the enrollment, the amount of immunosuppressant used =10mg / day oral prednisone for more than 2 weeks

• clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction, unstable or severe angina, coronary artery bypass surgery, congestive heart failure, and room requiring medical intervention within the first 6 months of enrollment arrhythmia, left ventricular ejection fraction <50%

• severe allergies

• severe mental disorder

• abnormal blood coagulation function (PT>16s, APTT>53s, TT>21s, Fib<1.5g/L), bleeding tendency or receiving thrombolysis or anticoagulant therapy

• previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, severe lung damage, etc

• other situations evaluated by investigators not meet the enrollment

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Perioperative Period
• Squamous Cell Carcinoma

Intervention

Drug:
• teripalimab plus chemotherapy
teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
• chemotherapy plus teripalimab
paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3

Locations

Country	Name	City	State
China	Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response rate	the proportion of patients got pathological complete response rate	two months
Secondary	occurrence rate of adverse events	the occurrence of adverse events	three month
Secondary	disease-free survival rate	the proportion of patients without relapse	three years